研究人员开发出一种名为 Phage Tn-seq(转座子测序)的新方法,旨在解决目前对噬菌体功能了解不足的问题,并为应对日益严重的抗生素耐药性提供新的治疗策略 1。抗生素耐药性预计到 2050 年每年将导致超过 800 万人死亡,凸显了探索替代疗法的紧迫性 1。该方法结合了转座子插入与 DNA 测序技术,能够快速识别噬菌体的关键基因并向其基因组中插入新的遗传物质 1。
在技术实现上,研究团队利用细菌自身的 CRISPR-Cas 免疫系统作为筛选工具,而非传统的抗生素抗性基因标记方式 1。为了验证该方法的可行性,实验成功将编码绿色荧光蛋白的基因插入噬菌体基因组,使受感染的细菌细胞发出绿光 1。这一突破为未来改造噬菌体以攻击生物膜等顽固感染源奠定了基础 1。尽管噬菌体疗法潜力巨大,但新西兰目前由于监管障碍和相关知识的空白,尚未将其作为常规医疗手段提供 1。
Antibiotic resistance is projected to cause more than 8 million deaths annually by 2050, driving the urgent search for alternative therapeutic strategies 1. In response, researchers have developed a novel technique called Phage Tn-seq, which integrates transposon insertion with DNA sequencing to rapidly identify essential genes in bacteriophages and insert new genetic material into their genomes 1. This advancement aims to overcome current limitations in understanding phage functionality, potentially enabling the creation of engineered viruses capable of targeting stubborn infections such as biofilms 1.
The methodology distinguishes itself by utilizing the bacterial CRISPR-Cas immune system as a screening tool, rather than relying on traditional antibiotic resistance markers 1. The feasibility of this approach was validated through successful experiments where a gene encoding green fluorescent protein was inserted into a phage genome, causing infected bacterial cells to emit green light 1. Despite these scientific breakthroughs, routine phage therapy remains unavailable in New Zealand due to regulatory barriers and existing knowledge gaps regarding these bacterial-killing viruses 1.
评论
还没有评论,欢迎留下第一条。